CoChat
Sign Up
Cited by 77

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.

Therapeutic targeting of senescent cells in the CNS

Riessland, Markus, Ximerakis, Methodios, Jarjour, Andrew A., Zhang, Bin, Orr, Miranda E.·2024·Nature Reviews Drug Discovery
DOI 10.1038/s41573-024-01033-zPMC PMC11927922
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41573-024-01033-z

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 228

  1. Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961). · DOI · Paper page
  2. Lundblad, V. & Szostak, J. W. A mutant with a defect in telomere elongation leads to senescence in yeast. Cell 57, 633–643 (1989). · DOI
  3. Harley, C. B., Futcher, A. B. & Greider, C. W. Telomeres shorten during ageing of human fibroblasts. Nature 345, 458–460 (1990). · DOI · Paper page
  4. Minamino, T. et al. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 105, 1541–1544 (2002). · DOI · Paper page
  5. Arendt, T., Rodel, L., Gartner, U. & Holzer, M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer’s disease. Neuroreport 7, 3047–3049 (1996). · DOI · Paper page
  6. McShea, A., Harris, P. L., Webster, K. R., Wahl, A. F. & Smith, M. A. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer’s disease. Am. J. Pathol. 150, 1933–1939 (1997).
  7. Coppe, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99–118 (2010). · DOI · Paper page
  8. Wiley, C. D. & Campisi, J. The metabolic roots of senescence: mechanisms and opportunities for intervention. Nat. Metab. 3, 1290–1301 (2021). · DOI · Paper page
  9. Nishio, K., Inoue, A., Qiao, S., Kondo, H. & Mimura, A. Senescence and cytoskeleton: overproduction of vimentin induces senescent-like morphology in human fibroblasts. Histochem. Cell Biol. 116, 321–327 (2001). · DOI · Paper page
  10. Dehkordi, S. K. et al. Profiling senescent cells in human brains reveals neurons with CDKN2D/p19 and tau neuropathology. Nat. Aging 1, 1107–1116 (2021). · DOI · Paper page
  11. Lee, B. Y. et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 5, 187–195 (2006). · DOI · Paper page
  12. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995). · DOI · Paper page
  13. Bittles, A. H. & Harper, N. Increased glycolysis in ageing cultured human diploid fibroblasts. Biosci. Rep. 4, 751–756 (1984). · DOI
  14. Flor, A. C., Wolfgeher, D., Wu, D. & Kron, S. J. A signature of enhanced lipid metabolism, lipid peroxidation and aldehyde stress in therapy-induced senescence. Cell Death Discov. 3, 17075 (2017). · DOI
  15. Song, Q. et al. Integrated multi-omics approach revealed cellular senescence landscape. Nucleic Acids Res. 50, 10947–10963 (2022). · DOI
  16. Gureghian, V. et al. A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma. Cancer Gene Ther. 30, 1330–1345 (2023). · DOI
  17. Xu, P. et al. The landscape of human tissue and cell type specific expression and co-regulation of senescence genes. Mol. Neurodegener. 17, 5 (2022). · DOI · Paper page
  18. Moh, C. et al. Cell cycle deregulation in the neurons of Alzheimer’s disease. Results Probl. Cell Differ. 53, 565–576 (2011). · DOI
  19. Yang, Y., Mufson, E. J. & Herrup, K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease. J. Neurosci. 23, 2557–2563 (2003). · DOI · Paper page
  20. Fujimaki, K. et al. Graded regulation of cellular quiescence depth between proliferation and senescence by a lysosomal dimmer switch. Proc. Natl Acad. Sci. USA 116, 22624–22634 (2019). · DOI
  21. Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. Nature 593, 405–410 (2021). · DOI · Paper page
  22. Goedert, M., Clavaguera, F. & Tolnay, M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 33, 317–325 (2010). · DOI
  23. Hussong, S. A. et al. Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy. Nat. Commun. 14, 2367 (2023). · DOI
  24. Ting, K. K. et al. Vascular senescence and leak are features of the early breakdown of the blood-brain barrier in Alzheimer’s disease models. Geroscience 45, 3307–3331 (2023). · DOI
  25. Bae, E. J. et al. TNF-alpha promotes alpha-synuclein propagation through stimulation of senescence-associated lysosomal exocytosis. Exp. Mol. Med. 54, 788–800 (2022). · DOI
  26. Sun, J. K. et al. Chronic alcohol metabolism results in DNA repair infidelity and cell cycle-induced senescence in neurons. Aging Cell 22, e13772 (2023). · DOI
  27. Ogrodnik, M. et al. Obesity-induced cellular senescence drives anxiety and impairs neurogenesis. Cell Metab. 29, 1061–1077.e1068 (2019). · DOI · Paper page
  28. Chow, H. M. et al. Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence. Nat. Neurosci. 22, 1806–1819 (2019). · DOI · Paper page
  29. Schwab, N. et al. Neurons and glial cells acquire a senescent signature after repeated mild traumatic brain injury in a sex-dependent manner. Front. Neurosci. 16, 1027116 (2022). · DOI
  30. Muralidharan, A. et al. Long-term male-specific chronic pain via telomere- and p53-mediated spinal cord cellular senescence. J. Clin. Invest. 132, e151817 (2022). · DOI
  31. Razzoli, M. et al. Social stress shortens lifespan in mice. Aging Cell 17, e12778 (2018). · DOI
  32. Diniz, B. S., Reynolds Iii, C. F., Sibille, E., Bot, M. & Penninx, B. Major depression and enhanced molecular senescence abnormalities in young and middle-aged adults. Transl. Psychiatry 9, 198 (2019). · DOI
  33. Diniz, B. S. et al. Association of molecular senescence markers in late-life depression with clinical characteristics and treatment outcome. JAMA Netw. Open 5, e2219678 (2022). · DOI
  34. Zhang, P. et al. Senolytic therapy alleviates Abeta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model. Nat. Neurosci. 22, 719–728 (2019). · DOI · Paper page
  35. Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428–435 (2016). · DOI · Paper page
  36. Demaria, M. et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 7, 165–176 (2017). · DOI · Paper page
  37. Erlangga, Z. et al. The effect of prolonged intermittent fasting on autophagy, inflammasome and senescence genes expressions: an exploratory study in healthy young males. Hum. Nutr. Metab. 32, 200189 (2023). · DOI
  38. Fontana, L., Nehme, J. & Demaria, M. Caloric restriction and cellular senescence. Mech. Ageing Dev. 176, 19–23 (2018). · DOI · Paper page
  39. Jang, Y. et al. Endurance exercise prevents metabolic distress-induced senescence in the hippocampus. Med. Sci. Sports Exerc. 51, 2012–2024 (2019). · DOI · Paper page
  40. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655–1657 (2002). · DOI · Paper page
  41. Akinleye, A., Avvaru, P., Furqan, M., Song, Y. & Liu, D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J. Hematol. Oncol. 6, 88 (2013). · DOI
  42. Ortiz, M. A. et al. Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition. Cell Commun. Signal. 19, 67 (2021). · DOI
  43. Anerillas, C. et al. Early SRC activation skews cell fate from apoptosis to senescence. Sci. Adv. 8, eabm0756 (2022). · DOI · Paper page
  44. Roos, C. M. et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 15, 973–977 (2016). · DOI · Paper page
  45. Palmer, A. K. et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell 18, e12950 (2019). · DOI · Paper page
  46. Novais, E. J. et al. Long-term treatment with senolytic drugs dasatinib and quercetin ameliorates age-dependent intervertebral disc degeneration in mice. Nat. Commun. 12, 5213 (2021). · DOI · Paper page
  47. Hochhaus, A. et al. European leukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34, 966–984 (2020). · DOI · Paper page
  48. Riessland, M. & Orr, M. E. Translating the biology of aging into new therapeutics for Alzheimer’s disease: senolytics. J. Prev. Alzheimers Dis. 10, 633–646 (2023).
  49. Garbarino, V. R. et al. Evaluation of exploratory fluid biomarker results from a phase 1 senolytic trial in mild Alzheimer’s disease. Preprint at Res. Sq. https://doi.org/10.21203/rs.3.rs-3994894/v1 (2024). · DOI
  50. Yousefzadeh, M. J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36, 18–28 (2018). · DOI · Paper page
  51. Kumar, R. M. et al. Fisetin in cancer: attributes, developmental aspects, and nanotherapeutics. Pharmaceuticals 16, 196 (2023). · DOI
  52. Viñas, P., Martínez-Castillo, N., Campillo, N. & Hernández-Córdoba, M. Directly suspended droplet microextraction with in injection-port derivatization coupled to gas chromatography–mass spectrometry for the analysis of polyphenols in herbal infusions, fruits and functional foods. J. Chromatogr. A 1218, 639–646 (2011). · DOI
  53. Sundarraj, K., Raghunath, A. & Perumal, E. A review on the chemotherapeutic potential of fisetin: in vitro evidences. Biomed. Pharmacother. 97, 928–940 (2018). · DOI
  54. Currais, A. et al. Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer’s disease transgenic mice. Aging Cell 13, 379–390 (2014). · DOI
  55. He, W. B., Abe, K. & Akaishi, T. Oral administration of fisetin promotes the induction of hippocampal long-term potentiation in vivo. J. Pharmacol. Sci. 136, 42–45 (2018). · DOI
  56. Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J. & Robbins, P. D. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J. 290, 1362–1383 (2023). · DOI
  57. Mehta, P., Pawar, A., Mahadik, K. & Bothiraja, C. Emerging novel drug delivery strategies for bioactive flavonol fisetin in biomedicine. Biomed. Pharmacother. 106, 1282–1291 (2018). · DOI
  58. Jornada, D. H. et al. The prodrug approach: a successful tool for improving drug solubility. Molecules 21, 42 (2015). · DOI
  59. Herrmann, I. K., Wood, M. J. A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748–759 (2021). · DOI
  60. Torchilin, V. P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 13, 813–827 (2014). · DOI
  61. Hoter, A., El-Sabban, M. E. & Naim, H. Y. The HSP90 family: structure, regulation, function, and implications in health and disease. Int. J. Mol. Sci. 19, 2560 (2018). · DOI · Paper page
  62. Uryu, K. et al. Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. Am. J. Pathol. 168, 947–961 (2006). · DOI
  63. Tortosa, E. et al. Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J. Alzheimers Dis. 17, 319–325 (2009). · DOI
  64. Fuhrmann-Stroissnigg, H. et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat. Commun. 8, 422 (2017). · DOI · Paper page
  65. Wang, D. X. et al. GDF11 slows excitatory neuronal senescence and brain ageing by repressing p21. Nat. Commun. 14, 7476 (2023). · DOI
  66. Hardwick, J. M. & Soane, L. Multiple functions of BCL-2 family proteins. Cold Spring Harb. Perspect. Biol. 5, a008722 (2013). · DOI
  67. Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008). · DOI · Paper page
  68. Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78–83 (2016). · DOI · Paper page
  69. Nakamura, A. et al. Bcl-xL is essential for the survival and function of differentiated neurons in the cortex that control complex behaviors. J. Neurosci. 36, 5448–5461 (2016). · DOI
  70. Koessinger, A. L. et al. Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Cell Death Differ. 29, 2089–2104 (2022). · DOI
  71. He, Y. et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat. Commun. 11, 1996 (2020). · DOI · Paper page
  72. Agostini, A. et al. Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles. Angew. Chem. Int. Ed. Engl. 51, 10556–10560 (2012). · DOI
  73. Piechota, M. et al. Is senescence-associated beta-galactosidase a marker of neuronal senescence? Oncotarget 7, 81099–81109 (2016). · DOI
  74. Hemann, M. T. & Lowe, S. W. The p53–Bcl-2 connection. Cell Death Differ. 13, 1256–1259 (2006). · DOI
  75. He, Y. et al. Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity. Aging Cell 19, e13117 (2020). · DOI
  76. Lane, N. et al. A phase 2, randomized, double-blind, placebo-controlled study of senolytic molecule UBX0101 in the treatment of painful knee osteoarthritis. Osteoarthr. Cartil. 29, S52–S53 (2021). · DOI
  77. Yoon, Y. S. et al. Senescence and impaired DNA damage responses in alpha-synucleinopathy models. Exp. Mol. Med. 54, 115–128 (2022). · DOI
  78. Wei, S. J. et al. Ketogenic diet induces p53-dependent cellular senescence in multiple organs. Sci. Adv. 10, eado1463 (2024). · DOI
  79. West, A. C. & Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30–39 (2014). · DOI · Paper page
  80. Crochemore, C., Fernandez-Molina, C., Montagne, B., Salles, A. & Ricchetti, M. CSB promoter downregulation via histone H3 hypoacetylation is an early determinant of replicative senescence. Nat. Commun. 10, 5576 (2019). · DOI
  81. Cheung, K. L., Kim, C. & Zhou, M. M. The functions of BET proteins in gene transcription of biology and diseases. Front. Mol. Biosci. 8, 728777 (2021). · DOI
  82. Hargreaves, D. C., Horng, T. & Medzhitov, R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138, 129–145 (2009). · DOI
  83. Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755–763 (2015). · DOI · Paper page
  84. Yang, M. et al. Transcriptome analysis of human OXR1 depleted cells reveals its role in regulating the p53 signaling pathway. Sci. Rep. 5, 17409 (2015). · DOI
  85. Zhang, X. et al. Oxidation resistance 1 is a novel senolytic target. Aging Cell 17, e12780 (2018). · DOI · Paper page
  86. Meiners, F. et al. Computational identification of natural senotherapeutic compounds that mimic dasatinib based on gene expression data. Sci. Rep. 14, 6286 (2024). · DOI
  87. Childs, B. G., Baker, D. J., Kirkland, J. L., Campisi, J. & van Deursen, J. M. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 15, 1139–1153 (2014). · DOI · Paper page
  88. Salminen, A. & Kaarniranta, K. Control of p53 and NF-κB signaling by WIP1 and MIF: role in cellular senescence and organismal aging. Cell Signal. 23, 747–752 (2011). · DOI · Paper page
  89. Stagni, V., Ferri, A., Cirotti, C. & Barilà, D. ATM kinase-dependent regulation of autophagy: a key player in senescence? Front. Cell Dev. Biol. 8, 599048 (2020). · DOI
  90. Hewitt, G. & Korolchuk, V. I. Repair, reuse, recycle: the expanding role of autophagy in genome maintenance. Trends Cell Biol. 27, 340–351 (2017). · DOI
  91. Zou, Z., Tao, T., Li, H. & Zhu, X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 10, 31 (2020). · DOI
  92. Neufeld, T. P. TOR-dependent control of autophagy: biting the hand that feeds. Curr. Opin. Cell Biol. 22, 157–168 (2010). · DOI
  93. Lamming, D. W., Ye, L., Sabatini, D. M. & Baur, J. A. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J. Clin. Invest. 123, 980–989 (2013). · DOI · Paper page
  94. Wang, R. et al. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism. Aging Cell 16, 564–574 (2017). · DOI · Paper page
  95. Li, J., Kim, S. G. & Blenis, J. Rapamycin: one drug, many effects. Cell Metab. 19, 373–379 (2014). · DOI · Paper page
  96. Fielder, E. et al. Anti-inflammatory treatment rescues memory deficits during aging in Nfkb1−/− mice. Aging Cell 19, e13188 (2020). · DOI · Paper page
  97. Israël, A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb. Perspect. Biol. 2, a000158 (2010). · DOI
  98. Zhang, L. et al. Novel small molecule inhibition of IKK/NF-κB activation reduces markers of senescence and improves healthspan in mouse models of aging. Aging Cell 20, e13486 (2021). · DOI
  99. Zhao, J. et al. Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation. PLoS Biol. 16, e2004663 (2018). · DOI
  100. Englund, D. A. et al. Senotherapeutic drug treatment ameliorates chemotherapy-induced cachexia. JCI Insight 9, e169512 (2024). · DOI
  101. Saha, R. N., Jana, M. & Pahan, K. MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65. J. Immunol. 179, 7101–7109 (2007). · DOI
  102. Khalil, R., Diab-Assaf, M. & Lemaitre, J. M. Emerging therapeutic approaches to target the dark side of senescent cells: new hopes to treat aging as a disease and to delay age-related pathologies. Cells 12, 915 (2023). · DOI
  103. Alimbetov, D. et al. Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2. Biogerontology 17, 305–315 (2016). · DOI · Paper page
  104. Tabet, N. & Feldmand, H. Ibuprofen for Alzheimer’s disease. Cochrane Database Syst. Rev. 2, CD004031 (2003).
  105. Marin, I., Serrano, M. & Pietrocola, F. Recent insights into the crosstalk between senescent cells and CD8 T lymphocytes. NPJ Aging 9, 8 (2023). · DOI
  106. Giannoula, Y., Kroemer, G. & Pietrocola, F. Cellular senescence and the host immune system in aging and age-related disorders. Biomed. J. 46, 100581 (2023). · DOI
  107. Lee, S. et al. A guide to senolytic intervention in neurodegenerative disease. Mech. Ageing Dev. 200, 111585 (2021). · DOI
  108. Lear, T. B. & Finkel, T. Senolytic vaccination: a new mandate for cardiovascular health? J. Cardiovasc. Aging 2, 17 (2022).
  109. Saade, M., Araujo de Souza, G., Scavone, C. & Kinoshita, P. F. The role of GPNMB in inflammation. Front. Immunol. 12, 674739 (2021). · DOI · Paper page
  110. Huang, J. et al. Emerging role of dipeptidyl peptidase-4 in autoimmune disease. Front. Immunol. 13, 830863 (2022). · DOI
  111. Hamada, M. et al. Urokinase-type plasminogen activator receptor (uPAR) in inflammation and disease: a unique inflammatory pathway activator. Biomedicines 12, 1167 (2024). · DOI
  112. Kaur, P. et al. Combining stem cell rejuvenation and senescence targeting to synergistically extend lifespan. Aging 14, 8270–8291 (2022).
  113. Ziegler, D. V., Martin, N. & Bernard, D. Cellular senescence links mitochondria–ER contacts and aging. Commun. Biol. 4, 1323 (2021). · DOI
  114. Kim, S. et al. Supramolecular senolytics via intracellular oligomerization of peptides in response to elevated reactive oxygen species levels in aging cells. J. Am. Chem. Soc. 145, 21991–22008 (2023). · DOI
  115. Liao, K. M. et al. Senomorphic effect of diphenyleneiodonium through AMPK/MFF/DRP1 mediated mitochondrial fission. Biomed. Pharmacother. 162, 114616 (2023). · DOI
  116. Vijay Kumar, M. J., Morales, R. & Tsvetkov, A. S. G-quadruplexes and associated proteins in aging and Alzheimer’s disease. Front. Aging 4, 1164057 (2023). · DOI
  117. Saunderson, E. A. et al. Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors. Nat. Commun. 8, 1450 (2017). · DOI
  118. Mohs, R. C. & Greig, N. H. Drug discovery and development: role of basic biological research. Alzheimers Dement. 3, 651–657 (2017).
  119. Kurauchi, Y., Noma, K., Hisatsune, A., Seki, T. & Katsuki, H. Na+, K+-ATPase inhibition induces neuronal cell death in rat hippocampal slice cultures: association with GLAST and glial cell abnormalities. J. Pharmacol. Sci. 138, 167–175 (2018). · DOI
  120. Robinson, E. J. et al. Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1. Cell Death Discov. 4, 107 (2018). · DOI
  121. Kassed, C. A., Willing, A. E., Garbuzova-Davis, S., Sanberg, P. R. & Pennypacker, K. R. Lack of NF-kappaB p50 exacerbates degeneration of hippocampal neurons after chemical exposure and impairs learning. Exp. Neurol. 176, 277–288 (2002). · DOI
  122. Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554–8559 (2001). · DOI · Paper page
  123. Lopez-Seijas, J. et al. Development of new non-viral systems for genetic modification of senescent cells. Mol. Ther. Nucleic Acids 32, 302–317 (2023). · DOI
  124. Marchi, N. et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med. 2, 37 (2004). · DOI
  125. Friden, P. M. et al. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl Acad. Sci. USA 88, 4771–4775 (1991). · DOI
  126. Pornnoppadol, G. et al. Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs. Cell Chem. Biol. 31, 361–372.e368 (2024). · DOI
  127. Pardridge, W. M. Drug transport across the blood–brain barrier. J. Cereb. Blood Flow Metab. 32, 1959–1972 (2012). · DOI · Paper page
  128. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2, 3–14 (2005). · DOI · Paper page
  129. Alavijeh, M. S., Chishty, M., Qaiser, M. Z. & Palmer, A. M. Drug metabolism and pharmacokinetics, the blood–brain barrier, and central nervous system drug discovery. NeuroRx 2, 554–571 (2005). · DOI
  130. Yabluchanskiy, A. et al. Pharmacological or genetic depletion of senescent astrocytes prevents whole brain irradiation-induced impairment of neurovascular coupling responses protecting cognitive function in mice. Geroscience 42, 409–428 (2020). · DOI
  131. Ng, P. Y., Zhang, C., Li, H. & Baker, D. J. Senescence targeting methods impact Alzheimer’s disease features in 3xTg mice. J. Alzheimers Dis. 97, 1751–1763 (2024). · DOI
  132. Karpel-Massler, G. et al. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Nat. Commun. 8, 1067 (2017). · DOI
  133. Crespo-Garcia, S. et al. Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results. Nat. Med. 30, 443–454 (2024). · DOI
  134. West, S., Nolan, S. J. & Newton, R. Surgery for epilepsy: a systematic review of current evidence. Epileptic Disord. 18, 113–121 (2016). · DOI
  135. Wu, J. W. et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19, 1085–1092 (2016). · DOI · Paper page
  136. Franzmeier, N. et al. Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nat. Commun. 13, 1362 (2022). · DOI
  137. Puigdellivol, M. et al. The microglial P2Y6 receptor mediates neuronal loss and memory deficits in neurodegeneration. Cell Rep. 37, 110148 (2021). · DOI
  138. Milde, S. et al. Inflammatory neuronal loss in the substantia nigra induced by systemic lipopolysaccharide is prevented by knockout of the P2Y6 receptor in mice. J. Neuroinflamm. 18, 225 (2021). · DOI
  139. Dundee, J. M., Puigdellivol, M., Butler, R., Cockram, T. O. J. & Brown, G. C. P2Y6 receptor-dependent microglial phagocytosis of synapses mediates synaptic and memory loss in aging. Aging Cell 22, e13761 (2023). · DOI
  140. Maynard, J. & Hart, P. The opportunities and use of imaging to measure target engagement. SLAS Discov. 25, 127–136 (2020). · DOI
  141. Matthews, P. M., Rabiner, E. A., Passchier, J. & Gunn, R. N. Positron emission tomography molecular imaging for drug development. Br. J. Clin. Pharmacol. 73, 175–186 (2012). · DOI
  142. Brickute, D. et al. Design, synthesis, and evaluation of a novel PET imaging agent targeting lipofuscin in senescent cells. RSC Adv. 12, 26372–26381 (2022). · DOI
  143. Krueger, M. A. et al. Abstract 1146: [18F]FPyGal: a novel ß-galactosidase specific PET tracer for in vivo imaging of tumor senescence. Cancer Res. 79, 1146 (2019). · DOI
  144. Benavides, S. H., Monserrat, A. J., Farina, S. & Porta, E. A. Sequential histochemical studies of neuronal lipofuscin in human cerebral cortex from the first to the ninth decade of life. Arch. Gerontol. Geriatr. 34, 219–231 (2002). · DOI
  145. Rossi, M. & Abdelmohsen, K. The emergence of senescent surface biomarkers as senotherapeutic targets. Cells 10, 1740 (2021). · DOI · Paper page
  146. Poblocka, M. et al. Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker. Sci. Rep. 11, 20358 (2021). · DOI · Paper page
  147. Fu, R., Carroll, L., Yahioglu, G., Aboagye, E. O. & Miller, P. W. Antibody fragment and affibody immunopet imaging agents: radiolabelling strategies and applications. ChemMedChem 13, 2466–2478 (2018). · DOI
  148. Liu, Y. et al. Expression of p16INK4a in peripheral blood T-cells is a biomarker of human aging. Aging Cell 8, 439–448 (2009). · DOI · Paper page
  149. Justice, J. N. et al. Caloric restriction intervention alters specific circulating biomarkers of the senescence-associated secretome in middle-aged and older adults with obesity and prediabetes in an 18-week randomized controlled trial. J. Gerontol. A Biol. Sci. Med. Sci. 79, glad214 (2024). · DOI
  150. Mitin, N. et al. A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer. NPJ Breast Cancer 8, 103 (2022). · DOI
  151. Basisty, N., Kale, A., Patel, S., Campsi, J. & Schilling, B. The power of proteomics to monitor senescence-associated secretory phenotypes and beyond: toward clinical applications. Expert Rev. Proteomics 17, 297–308 (2020). · DOI · Paper page
  152. Vamathevan, J. et al. Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov. 18, 463–477 (2019). · DOI · Paper page
  153. Waring, M. J. et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14, 475–486 (2015). · DOI · Paper page
  154. Hughes, B. K., Wallis, R. & Bishop, C. L. Yearning for machine learning: applications for the classification and characterisation of senescence. Cell Tissue Res. 394, 1–16 (2023). · DOI
  155. Ito, T. K. et al. A crucial role for CDC42 in senescence-associated inflammation and atherosclerosis. PLoS ONE 9, e102186 (2014). · DOI
  156. Kerber, R. A., O’Brien, E. & Cawthon, R. M. Gene expression profiles associated with aging and mortality in humans. Aging Cell 8, 239–250 (2009). · DOI
  157. Khadirnaikar, S., Chatterjee, A. & Shukla, S. Identification and characterization of senescence phenotype in lung adenocarcinoma with high drug sensitivity. Am. J. Pathol. 191, 1966–1973 (2021). · DOI
  158. Pun, F. W. et al. A comprehensive AI-driven analysis of large-scale omic datasets reveals novel dual-purpose targets for the treatment of cancer and aging. Aging Cell 22, e14017 (2023). · DOI
  159. Hughes, J. P., Rees, S., Kalindjian, S. B. & Philpott, K. L. Principles of early drug discovery. Br. J. Pharmacol. 162, 1239–1249 (2011). · DOI · Paper page
  160. Batool, M., Ahmad, B. & Choi, S. A structure-based drug discovery paradigm. Int. J. Mol. Sci. 20, 2783 (2019). · DOI
  161. Avelar, R. A. et al. A multidimensional systems biology analysis of cellular senescence in aging and disease. Genome Biol. 21, 91 (2020). · DOI · Paper page
  162. Mehegan, L. & Rainville, C. 2021 AARP survey on the perceptions related to a dementia diagnosis: adults age 40+. aarp.org https://www.aarp.org/content/dam/aarp/research/surveys_statistics/health/2021/dementia-diagnosis-perceptions.doi.10.26419-2Fres.00471.001.pdf (AARP Research, 2021). · DOI
  163. Watson, R., Sanson-Fisher, R., Bryant, J. & Mansfield, E. Dementia is the second most feared condition among Australian health service consumers: results of a cross-sectional survey. BMC Public Health 23, 876 (2023). · DOI · Paper page
  164. Turnquist, C. et al. p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. Cell Death Differ. 23, 1515–1528 (2016). · DOI
  165. Wu, D., Sun, J. K. & Chow, K. H. Neuronal cell cycle reentry events in the aging brain are more prevalent in neurodegeneration and lead to cellular senescence. PLoS Biol. 22, e3002559 (2024). · DOI
  166. Jin, W. N. et al. Neuroblast senescence in the aged brain augments natural killer cell cytotoxicity leading to impaired neurogenesis and cognition. Nat. Neurosci. 24, 61–73 (2021). · DOI · Paper page
  167. Das, M. M. & Svendsen, C. N. Astrocytes show reduced support of motor neurons with aging that is accelerated in a rodent model of ALS. Neurobiol. Aging 36, 1130–1139 (2015). · DOI
  168. Vazquez-Villasenor, I. et al. Expression of p16 and p21 in the frontal association cortex of ALS/MND brains suggests neuronal cell cycle dysregulation and astrocyte senescence in early stages of the disease. Neuropathol. Appl. Neurobiol. 46, 171–185 (2020). · DOI
  169. Trias, E. et al. Emergence of microglia bearing senescence markers during paralysis progression in a rat model of inherited ALS. Front. Aging Neurosci. 11, 42 (2019). · DOI · Paper page
  170. Torres, P. et al. A motor neuron disease mouse model reveals a non-canonical profile of senescence biomarkers. Dis. Model. Mech. 15, dmm049059 (2022). · DOI
  171. Borgonetti, V. & Galeotti, N. Rosmarinic acid reduces microglia senescence: a novel therapeutic approach for the management of neuropathic pain symptoms. Biomedicines 10, 1468 (2022). · DOI
  172. Lim, S. et al. Senolytic therapy for cerebral ischemia-reperfusion injury. Int. J. Mol. Sci. 22, 11967 (2021). · DOI
  173. Lu, K. J. et al. Ability of local clearance of senescent cells in ipsilateral hemisphere to mitigate acute ischemic brain injury in mice. Int. J. Biol. Sci. 19, 2835–2847 (2023). · DOI
  174. Torres-Querol, C. et al. Acute ischemic stroke triggers a cellular senescence-associated secretory phenotype. Sci. Rep. 11, 15752 (2021). · DOI
  175. Ritzel, R. M. et al. Old age increases microglial senescence, exacerbates secondary neuroinflammation, and worsens neurological outcomes after acute traumatic brain injury in mice. Neurobiol. Aging 77, 194–206 (2019). · DOI · Paper page
  176. Skowronska-Krawczyk, D. et al. P16INK4a upregulation mediated by SIX6 defines retinal ganglion cell pathogenesis in glaucoma. Mol. Cell 59, 931–940 (2015). · DOI
  177. Yang, L. et al. SARS-CoV-2 infection causes dopaminergic neuron senescence. Cell Stem Cell 31, 196–211.e196 (2024). · DOI
  178. Salam, R. et al. Cellular senescence in malignant cells promotes tumor progression in mouse and patient glioblastoma. Nat. Commun. 14, 441 (2023). · DOI · Paper page
  179. Beltzig, L. et al. Senescence is the main trait induced by temozolomide in glioblastoma cells. Cancers 14, 2233 (2022). · DOI
  180. Nicaise, A. M. et al. Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proc. Natl Acad. Sci. USA 116, 9030–9039 (2019). · DOI
  181. Porkka, K. et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112, 1005–1012 (2008). · DOI · Paper page
  182. Costa, L. G., Garrick, J. M., Roquè, P. J. & Pellacani, C. Mechanisms of neuroprotection by quercetin: counteracting oxidative stress and more. Oxid. Med. Cell. Longev. 2016, 2986796 (2016). · DOI
  183. Rivera, F., Urbanavicius, J., Gervaz, E., Morquio, A. & Dajas, F. Some aspects of the in vivo neuroprotective capacity of flavonoids: bioavailability and structure-activity relationship. Neurotox. Res. 6, 543–553 (2004). · DOI
  184. Wang, C. et al. Combined use of dasatinib and quercetin alleviates overtraining-induced deficits in learning and memory through eliminating senescent cells and reducing apoptotic cells in rat hippocampus. Behav. Brain Res. 440, 114260 (2023). · DOI
  185. Krzystyniak, A. et al. Combination of dasatinib and quercetin improves cognitive abilities in aged male Wistar rats, alleviates inflammation and changes hippocampal synaptic plasticity and histone H3 methylation profile. Aging 14, 572–595 (2022). · DOI · Paper page
  186. Brandt, C. et al. The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. Neuropharmacology 140, 107–120 (2018). · DOI
  187. Kolosova, N. G. et al. Rapamycin suppresses brain aging in senescence-accelerated OXYS rats. Aging 5, 474–484 (2013). · DOI
  188. Van Skike, C. E. et al. mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging. Aging Cell 19, e13057 (2020). · DOI
  189. Hay, D. G. et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington’s disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 13, 1389–1405 (2004). · DOI
  190. Putcha, P. et al. Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J. Pharmacol. Exp. Ther. 332, 849–857 (2010). · DOI
  191. O’Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017). · DOI
  192. Iwasaki, A. Immune regulation of antibody access to neuronal tissues. Trends Mol. Med. 23, 227–245 (2017). · DOI
  193. Yang, X. S. et al. Ouabain suppresses the growth and migration abilities of glioma U-87MG cells through inhibiting the Akt/mTOR signaling pathway and downregulating the expression of HIF-1α. Mol. Med. Rep. 17, 5595–5600 (2018).
  194. Lan, Y. L. et al. Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na+/K+-ATPase α1 subunit. Biomed. Pharmacother. 103, 204–215 (2018). · DOI
  195. Storstein, L., Nore, A. K. & Sjaastad, O. Studies on digitalis. 23. Blood-brain barrier of digitoxin in humans. Clin. Cardiol. 2, 146–150 (1979). · DOI
  196. Tsyvunin, V., Shtrygol, S. & Shtrygol, D. Digoxin enhances the effect of antiepileptic drugs with different mechanism of action in the pentylenetetrazole-induced seizures in mice. Epilepsy Res. 167, 106465 (2020). · DOI
  197. Dvela-Levitt, M., Ami, H. C., Rosen, H., Shohami, E. & Lichtstein, D. Ouabain improves functional recovery following traumatic brain injury. J. Neurotrauma 31, 1942–1947 (2014). · DOI
  198. Erdogan, M. A., Kirazlar, M., Yigitturk, G. & Erbas, O. Digoxin exhibits neuroprotective properties in a rat model of dementia. Neurochem. Res. 47, 1290–1298 (2022). · DOI
  199. Hassan, J. W. & Bhatwadekar, A. D. Senolytics in the treatment of diabetic retinopathy. Front. Pharmacol. 13, 896907 (2022). · DOI
  200. Yamaguchi, R. & Perkins, G. Finding a panacea among combination cancer therapies. Cancer Res. 72, 18–23 (2012). · DOI

200 of 228 shown

Cited by

Sorted by citations

Metadata

Authors
Riessland, M., Ximerakis, M., Jarjour, A. A., Zhang, B., & Orr, M. E.
Venue
Nature Reviews Drug Discovery
Publisher
Springer Science and Business Media LLC
Published
2024-09-30
Volume
23
Issue
11
Pages
817-837
ISSN
  • 1474-1776
  • 1474-1784
DOI
10.1038/s41573-024-01033-z
PMC
PMC11927922
Cited by
77
References
97
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review